Regorafenib in Patients with Antiangiogenic-Naive and Chemotherapy-Refractory Advanced Colorectal Cancer: Results from a Phase IIb Trial

Imagem de Miniatura
Arquivos
art_RIECHELMANN_Regorafenib_in_Patients_with_AntiangiogenicNaive_and_ChemotherapyRefractory_Advanced_2019.PDF (990.11 KB)
Citações na Scopus
14
Tipo de produção
article
Data de publicação
2019
DOI
Scopus
Web of Science
PubMed
Título da Revista
ISSN da Revista
Título do Volume
Editora
WILEY
Autores
ISEJIMA, Alice M.
Citação
ONCOLOGIST, v.24, n.9, p.1180-1187, 2019
Projetos de Pesquisa
Unidades Organizacionais
Fascículo
Resumo
Background Regorafenib is a multikinase inhibitor with antiangiogenic effects that improves overall survival (OS) in metastatic colorectal cancer (mCRC) after failure of standard therapies. We investigated the efficacy and safety of regorafenib in antiangiogenic therapy-naive chemotherapy-refractory advanced colorectal cancer. Patients and Methods This single-center, single-arm, phase IIb study (NCT02465502) enrolled adults with mCRC whose disease had progressed on, or who were intolerant to, standard therapy, but who were antiangiogenic therapy-naive. Patients received regorafenib 160 mg once daily for 3 weeks per 4-week cycle. The primary endpoint was progression-free survival (PFS) rate at week 8. Results Of 59 treated patients, almost half had received at least four prior lines of therapy. Patients received a median of 86% of the planned dose. The week 8 PFS rate was 53% (95% confidence interval [CI], 39.1-64.3); median PFS was 3.5 months (95% CI, 1.8-3.6). Median OS was 7.4 months (95% CI, 5.3-8.9). Tumor response (RECIST version 1.1) was 2%, and metabolic response rate (criteria from the European Organisation for Research and Treatment of Cancer) was 41%. The most frequently reported regorafenib-related grade >= 3 adverse events were hypertension (36%), hand-foot skin reaction (HFSR, 25%), and hypophosphatemia (24%). There were no regorafenib-related deaths. An exploratory analysis showed that patients with grade >= 2 HFSR had longer OS (10.2 months) with regorafenib treatment versus those with grades 0-1 (5.4 months). Conclusion These findings support the antitumor activity of regorafenib in antiangiogenic-naive patients with chemotherapy-refractory mCRC. Implications for Practice The multikinase inhibitor regorafenib improved overall survival in the phase III CORRECT and CONCUR trials in heavily pretreated patients with treatment-refractory metastatic colorectal cancer (mCRC). Exploratory subgroup analysis from CONCUR suggested that regorafenib treatment prior to targeted therapy (including bevacizumab) may improve outcomes. In this single-center, single-arm phase IIb study, regorafenib demonstrated antitumor activity in 59 antiangiogenic-naive patients with chemotherapy-refractory mCRC. Further studies should assess the efficacy of regorafenib in this patient population, as well as explore the reasons behind improved outcomes among patients who had a metabolic response and those who developed hand-foot skin reaction.
Palavras-chave
Regorafenib, Colorectal neoplasms, Angiogenesis inhibitors, Computed tomography, Positron emission tomography
URI
https://observatorio.fm.usp.br/handle/OPI/33980
Referências
  1. [Anonymous], 2018, STIV REG TABL PACK I
  2. [Anonymous], 2018, STIV REG SUMM PROD C
  3. BEKAIISAAB TS, 2018, J CLIN ONCOL S, V36, p611A
  4. Boellaard R, 2010, EUR J NUCL MED MOL I, V37, P181, DOI 10.1007/s00259-009-1297-4
  5. BRUIX J, 2018, J CLIN ONCOL S, V36, p412A
  6. Bruix J, 2017, LANCET, V389, P56, DOI 10.1016/S0140-6736(16)32453-9
  7. Choi H, 2007, J CLIN ONCOL, V25, P1753, DOI 10.1200/JCO.2006.07.3049
  8. Demetri GD, 2013, LANCET, V381, P295, DOI 10.1016/S0140-6736(12)61857-1
  9. Eisenhauer EA, 2009, EUR J CANCER, V45, P228, DOI 10.1016/j.ejca.2008.10.026
  10. Grothey A, 2017, J CLIN ONCOL, V35, pS3619
  11. Grothey A, 2013, LANCET, V381, P303, DOI 10.1016/S0140-6736(12)61900-X
  12. Histed SN, 2012, NUCL MED COMMUN, V33, P349, DOI 10.1097/MNM.0b013e32834ec8a5
  13. Kim JH, 2016, ONCOTARGET, V7, P58105, DOI 10.18632/oncotarget.11171
  14. Li J, 2015, LANCET ONCOL, V16, P619, DOI 10.1016/S1470-2045(15)70156-7
  15. National Comprehensive Cancer Network, 2018, NCCN CLIN PRACT GUID
  16. Nogueira Fogace R, 2017, BRAZ J ONCOL, V13, P1
  17. Schmieder R, 2014, INT J CANCER, V135, P1487, DOI 10.1002/ijc.28669
  18. Shinagare AB, 2014, EUR J CANCER, V50, P981, DOI 10.1016/j.ejca.2013.11.037
  19. Shitara K, 2019, ANN ONCOL, V30, P259, DOI 10.1093/annonc/mdy526
  20. Tabernero J, 2014, EUR J CANCER, V50, P320, DOI 10.1016/j.ejca.2013.09.013
  21. Van Cutsem E, 2016, ANN ONCOL, V27, P1386, DOI 10.1093/annonc/mdw235
  22. Wahl RL, 2009, J NUCL MED, V50, p122S, DOI 10.2967/jnumed.108.057307
  23. Wilhelm SM, 2011, INT J CANCER, V129, P245, DOI 10.1002/ijc.25864
  24. Young H, 1999, EUR J CANCER, V35, P1773, DOI 10.1016/S0959-8049(99)00229-4

Coleções
Artigos e Materiais de Revistas Científicas - FM/MDR
Artigos e Materiais de Revistas Científicas - HC/ICESP
Artigos e Materiais de Revistas Científicas - LIM/24
Artigos e Materiais de Revistas Científicas - LIM/43
Artigos e Materiais de Revistas Científicas - ODS/03